Omnitura Therapeutics is commercializing Aneustat™, the world’s first multivalent immuno-oncology drug candidate. Our initial disease focus is prostate cancer. Market launch is planned for 2021 or early 2022.
Aneustat™ is orally delivered and non-toxic. It has been shown to kill cancer cells at all stages of development through apoptosis without developing drug resistance. In combination with FDA approved standard-of-care drugs, Aneustat™ is expected to significantly improve efficacy and quality of life while avoiding or postponing the onset of drug resistance common to standard-of-care drugs.
For cancer patients, Aneustat™ is designed to:
simultaneously reboot the immune system and normalize key metabolic processes and the tumor micro-environment
prevent proliferation of cancer and comorbid diseases
improve quality of life for cancer patients
reduce disease incidence
reduce healthcare costs arising from comorbidities